

[Alcuronium](#)

Not recommended as an essential medicine

Section:

[20. Muscle relaxants \(peripherally-acting\) and cholinesterase inhibitors](#)

Codes ATC: [M03AA01](#)

Indication

Muscle relaxants Code ICD11: [XM1638330014](#)

INN

Alcuronium chloride

Type de médicament

Chemical agent

Type de liste

Liste de base

Formulations

Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)

Historique des statuts LME

Ajouté pour la première fois en 1993 ([TRS 850](#))

Retiré en 2011 ([TRS 965](#))

Sexe

Tous

Âge

Adolescents et adultes

Équivalence thérapeutique

Des médicaments appartenant à la même classe pharmacologique peuvent être utilisés

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets](#).

Wikipédia

[Alcuronium](#)

[DrugBank](#)

[Alcuronium](#)

Résumé des preuves et recommandation du comité d'experts

Alcuronium was replaced by atracurium (with a square box) following a review of muscle relaxants on the the EML in 2011. Alcuronium has a slow onset and long duration of action, with more adverse effects than other non-depolarizing agents (1). It is no longer registered by stringent regulatory authorities (United States, United Kingdom, France). Atracurium has fewer adverse effects, although it can cause histamine release. Rocuronium and vecuronium have longer onset of action but decreased risk of tachycardia. Pancuronium has an even longer onset and duration of action. The Committee noted that the information in the review showed that, within the class, atracurium is cheaper than others except pancuronium (Table 7 in the application) and therefore recommended the replacement of alcuronium with atracurium (), due to its comparative effectiveness and safety profile, current availability, and cost. The Committee recommended that this section (Section 20) be reviewed before the next Expert Committee meeting, to consider which longer-acting agents were needed, and which were specifically useful in children. References: 1. Hunter JM. New neuromuscular blocking drugs. New England Journal of Medicine, 1995,332:1691-1699.